Seminars in Oncology
Volume 34, Issue 2 , Pages 75-84 , April 2007

Molecular Alterations Associated With Bladder Cancer Progression

  • Marta Sánchez-Carbayo

      Affiliations

    • Tumor Markers Group, Spanish National Cancer Center, Madrid, Spain.
    • Corresponding Author InformationAddress correspondence to Marta Sánchez-Carbayo, PhD, Group Leader, Tumor Markers Group, Spanish National Cancer Center, Melchor Fernández Almagro 3, 28029 Madrid, Spain.
    • ,
  • Carlos Cordon-Cardó

      Affiliations

    • Department of Pathology, Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.
    • Corresponding Author InformationAddress correspondence to Carlos Cordon-Cardo, MD, PhD, Director, Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

References 

  1. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799
  3. Wolff EM, Liang G, Jones PA. Mechanisms of disease: Genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol. 2005;2:502–510
  4. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer. 1999;80:904–908
  5. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998;16:3215–3218
  6. Dalbagni G, Presti J, Reuter V, et al. Genetic alterations in bladder cancer. Lancet. 1993;342:469–471
  7. Cordon-Cardo C, Reuter VE. Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol. 1997;14:123–132
  8. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–1959
  9. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  10. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33:828–841
  11. Mitra N, Indurkhya A. A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data. Health Econ. 2005;14:805–815
  12. El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10:20–25
  13. Reuter VE. Bladder (Risk and prognostic factors—A pathologist’s perspective). Urol Clin North Am. 1999;26:481–492
  14. Palou J, Sanchez-Martin FM, Rosales A, et al. Intravesical bacille Calmette-Guerin in the treatment of carcinoma in situ or high-grade superficial bladder carcinoma after radiotherapy for bladder carcinoma. BJU Int. 1999;83:429–431
  15. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181
  16. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109–118
  17. McBride OW, Swan DC, Santos E, et al. Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11. Nature. 1982;300:773–774
  18. Czerniak B, Cohen GL, Etkind P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992;23:1199–1204
  19. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res. 1998;58:5348–5353
  20. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973–6980
  21. Zhang ZT, Pak J, Shapiro E, et al. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59:3512–3517
  22. Reznikoff CA, Belair C, Savelieva E, et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 1994;8:2227–2240
  23. Chen CC, Shieh B, Jin YT, et al. Microarray profiling of gene expression patterns in bladder tumor cells treated with genistein. J Biomed Sci. 2001;8:214–222
  24. Liang G, Gonzales FA, Jones PA, et al. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2’-deoxycytidine. Cancer Res. 2002;62:961–966
  25. Tsunoda T, Koga H, Yokomizo A, et al. Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene. 2005;24:1396–1402
  26. Harding MA, Arden KC, Gildea JW, et al. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res. 2002;62:6981–6989
  27. Titus B, Frierson HF, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 2005;65:7320–7327
  28. Nicholson BE, Frierson HF, Conaway MR, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004;64:7813–7821
  29. Louhelainen JP, Hurst CD, Pitt E, et al. DBC1 re-expression alters the expression of multiple components of the plasminogen pathway. Oncogene. 2006;25:2409–2419
  30. Maxwell SA, Davies GE. Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci U S A. 2000;97:13009–13014
  31. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973–6980
  32. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 2001;61:2492–2499
  33. Sanchez-Carbayo M, Capodieci P, Cordon- Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: Loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol. 2003;162:609–618
  34. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Gen. 2003;33:90–96
  35. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res. 2004;10:3410–3421
  36. Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004;10:3800–3806
  37. Gomez-Roman JJ, Saenz P, Molina M, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res. 2005;11:459–465
  38. Kim JH, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest. 2005;85:532–549
  39. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res. 2005;11:4029–4036
  40. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–4055
  41. Aaboe M, Marcussen N, Jensen KM, et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer. 2005;93:1182–1190
  42. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–789
  43. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: Clinical aspects and in vitro functional characterization. Cancer Res. 2006;66:3434–3442
  44. Elsamman E, Fukumori T, Ewis AA, et al. Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. Urol Oncol. 2006;24:109–115
  45. Lu M, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002;8:171–179
  46. Primdahl H, Wikman FP, von der Maase H, et al. Allelic imbalances in human bladder cancer: Genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst. 2002;94:216–223
  47. Koed K, Wiuf C, Christensen LL, et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res. 2005;65:34–45
  48. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005;11:7012–7022
  49. Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405:837–846
  50. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001;2:1–4
  51. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006;168:93–103
  52. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847
  53. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001;194:349–357
  54. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 2000;157:787–794
  55. Visapaa H, Seligson D, Eeva M, et al. 8q24 amplification in transitional cell carcinoma of bladder. Appl Immunohistochem Mol Morphol. 2003;11:33–36
  56. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004;84:465–478
  57. Wild PJ, Kunz-Schughart LA, Stoehr R, et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol. 2005;27:385–391
  58. Kruger S, Mahnken A, Kausch I, et al. p16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol. 2005;47:463–467
  59. Kruger S, Mahnken A, Kausch I, et al. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology. 2006;67:105–109

PII: S0093-7754(06)00490-8

doi: 10.1053/j.seminoncol.2006.12.013

Seminars in Oncology
Volume 34, Issue 2 , Pages 75-84 , April 2007

Article Tools

* Image Usage & Resolution